A First of its Kind Approval Changes the Way We Think About Access

The Challenge

The Challenge

A clinical-stage pharmaceutical company faced a unique barrier in bringing its first product to market—seeking pan-tumor approval based on a genetic marker, rather than a traditional approval based on cancer type. They subsequently sought recognition for the product across relevant clinical compendia.

The IP Solution

The IP Solution

Our extensive experience shepherding dozens of products to market enabled us to develop a strategy unique to this product, opening access for patients to this practice-changing therapy. IP was critical in identifying how to make the best case for the product to the decision-makers at major guideline/compendia organizations.

Our well-established relationships with Key Opinion Leaders enabled us to gain insight through 1:1 engagement, as our meetings with leaders of compendia-developing organizations. IP’s talented team transformed this knowledge into action – providing medical writing assistance for compendia application submissions, planning and implementing an advisory board, and developing a publication strategy.

We engaged IP to help us identify KOLs in areas which our team didn’t have the level of comfort that we needed at the time, specifically Hematologists in Europe. Their execution was flawless.
Medical Director, Pharma/Biotech Company
The Result

The Results

Following FDA approval, the product was recognized across major clinical compendia for all approved indications, ensuring broad access for providers across the community and academic settings and ultimately for patients.

Related Case Studies

Healthcare policy changes interpreted in real-time

A European-based pharmaceutical company with several products in the US market was under pressure to interpret and respond to rapidly changing US healthcare policies which could potentially impact access for their portfolio of oncology products.

A comprehensive launch strategy leads to broad access

A biopharmaceutical company was in the midst of bringing its first product to market with breakthrough therapy designation. The PDUFA date was fast approaching, and their small team needed guidance to steer them through the complicated access and reimbursement landscape.

Understanding the European Market

A mid-sized pharmaceutical company was looking to enter the European market through a compassionate use/early access pathway but lacked an understanding of the requirements specific to each country that would lead to broad access and reimbursement for their product across Europe.

View More Case Studies